{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:30:26Z","timestamp":1786685426613,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) show substantial therapeutic potential in advanced or metastatic solid malignancies, yet optimization of clinical benefit remains an unmet need. This systematic review and meta-analysis evaluates the pretreatment pan-immune-inflammation value (PIV) as a prognostic biomarker in ICI-treated solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted comprehensive searches in PubMed, EMBASE, Cochrane Library and Web of Science covering all records available up to January 2026. Hazard ratios (HRs) with 95% confidence intervals (CIs) were retrieved, and pooled analyses were performed using STATA 18.0 to quantify correlations between PIV and survival results. Overall survival (OS) was considered the primary outcome, with disease-free, progression-free, and recurrence-free survival (DFS\/PFS\/RFS) as secondary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two studies comprising 28 cohorts and 3,272 participants were incorporated. Multivariate meta-analysis detected that an elevated PIV was related to shorter OS (HR\u00a0=\u00a02.31; 95% CI: 2.02\u20132.65; P &amp;lt; 0.00001) and inferior DFS\/PFS\/RFS (HR\u00a0=\u00a01.79; 95% CI: 1.42\u20132.26; P &amp;lt; 0.00001). Subgroup analyses denoted that follow-up duration, geographic region, PIV cutoff definitions, and cancer type may have modified the predictive performance of PIV for DFS\/PFS\/RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients receiving ICIs, an elevated pretreatment PIV may serve as a potentially useful adverse prognostic biomarker for survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261290575.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1841286","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:24:17Z","timestamp":1786685057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The prognostic value of the pan-immune-inflammation value in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Le","family":"Yang","sequence":"first","affiliation":[{"name":"The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University","place":["Urumqi, China"]},{"name":"Xinjiang Key Laboratory of Oncology, The Third Affiliated Teaching Hospital (Affiliated Cancer Hospital) of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University","place":["Urumqi, China"]},{"name":"Xinjiang Key Laboratory of Oncology, The Third Affiliated Teaching Hospital (Affiliated Cancer Hospital) of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munawar","family":"Anwar","sequence":"additional","affiliation":[{"name":"The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University","place":["Urumqi, China"]},{"name":"Xinjiang Key Laboratory of Oncology, The Third Affiliated Teaching Hospital (Affiliated Cancer Hospital) of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Medicine Department of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Dai","sequence":"additional","affiliation":[{"name":"Clinical Medicine Department of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeliya","family":"Yeerboli","sequence":"additional","affiliation":[{"name":"Clinical Medicine Department of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuqiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Medicine Department of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Medicine Department of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihui","family":"Shan","sequence":"additional","affiliation":[{"name":"The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University","place":["Urumqi, China"]},{"name":"Xinjiang Key Laboratory of Oncology, The Third Affiliated Teaching Hospital (Affiliated Cancer Hospital) of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Dong","sequence":"additional","affiliation":[{"name":"The Clinical Medical Research Center of Breast and Thyroid Tumor in Xinjiang, Tumor Hospital Affiliated to Xinjiang Medical University","place":["Urumqi, China"]},{"name":"Xinjiang Key Laboratory of Oncology, The Third Affiliated Teaching Hospital (Affiliated Cancer Hospital) of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"Medcomm (2020)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937902","article-title":"Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188758","article-title":"Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.067592","article-title":"Unraveling immunotherapy resistance in solid tumors: decoding mechanisms and charting future therapeutic landscapes","volume":"33","author":"Wang","year":"2025","journal-title":"Oncol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2020.1839519","article-title":"The role of nutrition in cancer patients","volume":"73","author":"Barreira","year":"2021","journal-title":"Nutr Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.31083\/fbl26995","article-title":"Role of tumor-associated macrophages in breast cancer immunotherapy","volume":"30","author":"He","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1186\/s12885-023-11366-4","article-title":"Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2024-0031","article-title":"Prognostic value of peripheral blood neutrophil\/lymphocyte ratio, platelet\/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in patients with advanced gastric cancer","volume":"16","author":"Fu","year":"2024","journal-title":"Immunotherapy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014134","article-title":"Targeting the neuro-immune crosstalk in breast cancer brain metastases","volume":"14","author":"Zou","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1674818","article-title":"The role of immune checkpoint molecules in cancers","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030749","article-title":"Biomarkers for outcome in metastatic melanoma in first line treatment with immune checkpoint inhibitors","volume":"11","author":"Mesti","year":"2023","journal-title":"Biomedicines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-01018-9","article-title":"A novel prognostic model using pan-immune-inflammation value and programmed death ligand 1 in patients with recurrent or metastatic head and neck squamous cell carcinoma receiving immune checkpoint inhibitors: a retrospective multicenter analysis","volume":"19","author":"Lien","year":"2024","journal-title":"Target Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326083","article-title":"Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2576639","article-title":"Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials","volume":"57","author":"Cheng","year":"2025","journal-title":"Ann Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.043","article-title":"The pan-immune-inflammation value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors","volume":"150","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14430-2","article-title":"Pretreatment pan-immune-inflammation value (PIV) in predicting therapeutic response and clinical outcomes of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma","volume":"31","author":"Feng","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13701-0","article-title":"Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer","volume":"15","author":"Gao","year":"2025","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02560-6","article-title":"PILE: a candidate prognostic score in cancer patients treated with immunotherapy","volume":"23","author":"Guven","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66813-4","article-title":"Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction","volume":"14","author":"Lei","year":"2024","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03833-y","article-title":"The association of immune-inflammation indices at multiple time points with treatment response and survival in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"23","author":"Li","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2024.2355279","article-title":"Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment","volume":"41","author":"Liang","year":"2024","journal-title":"Int J Hyperthermia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S461964","article-title":"The construction of a nomogram using the pan-immune-inflammation value combined with a PILE score for immunotherapy prediction prognosis in advanced NSCLC","volume":"16","author":"Ma","year":"2024","journal-title":"Cancer Manage Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010037","article-title":"Prognostic value of blood-based inflammatory markers in cancer patients receiving immune checkpoint inhibitors","volume":"17","author":"Midik","year":"2025","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14898","article-title":"Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort","volume":"14","author":"Qi","year":"2023","journal-title":"Thorac Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21095","article-title":"Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy","volume":"40","author":"Sooi","year":"2022","journal-title":"J Clin Oncol Conference: Annu Meeting Am Soc Clin Oncol ASCO"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.14744\/ejmo.2024.67906","article-title":"Baseline pan-immune-inflammation value is associated with clinical outcome in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors","volume":"8","author":"Su","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111792","article-title":"Comparison of prognostic values of seven immune indexes in advanced non-small-cell lung cancer treated with nivolumab: how effective can they be regarding our treatment decisions","volume":"60","author":"Ulas","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s471502","article-title":"Assessing the prognostic value of 13 inflammation-based scores in patients with unresectable or advanced biliary tract carcinoma after immunotherapy","volume":"13","author":"Wang","year":"2024","journal-title":"Immunotargets Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/agm2.70052","article-title":"A retrospective study of first-line immunotherapy for advanced non-small cell lung cancer in the elderly","volume":"8","author":"Yang","year":"2025","journal-title":"Aging Med (Milton)"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-022-04055-5","article-title":"The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study","volume":"148","author":"Yekeduz","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724443","article-title":"PIV and PILE score at baseline predict clinical outcome of anti-PD-1\/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12672-024-01267-8","article-title":"Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"He","year":"2024","journal-title":"Discov Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2017.09.009","article-title":"Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth","volume":"409","author":"Lyu","year":"2017","journal-title":"Cancer Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000010831","article-title":"Poor prognostic role of the pretreatment platelet counts in colorectal cancer: a meta-analysis","volume":"97","author":"Rao","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12890-020-1139-5","article-title":"Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis","volume":"20","author":"Yuan","year":"2020","journal-title":"BMC Pulm Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijsu.2015.07.681","article-title":"The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: a meta-analysis","volume":"21","author":"Xin-Ji","year":"2015","journal-title":"Int J Surg"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-35723-8_1","article-title":"Neutrophils in the tumor microenvironment","volume":"1224","author":"Wu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.4ri0818-311r","article-title":"Monocyte heterogeneity and functions in cancer","volume":"106","author":"Olingy","year":"2019","journal-title":"J Leukoc Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:24:18Z","timestamp":1786685058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":50,"alternative-id":["10.3389\/fonc.2026.1841286"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1841286","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1841286"}}